These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 33097791)

  • 21. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.
    McKay PF; Hu K; Blakney AK; Samnuan K; Brown JC; Penn R; Zhou J; Bouton CR; Rogers P; Polra K; Lin PJC; Barbosa C; Tam YK; Barclay WS; Shattock RJ
    Nat Commun; 2020 Jul; 11(1):3523. PubMed ID: 32647131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
    Jitender ; Vikram Kumar B; Singh S; Verma G; Kumar R; Mishra PM; Kumar S; Nagaraj SK; Nag J; Joy CM; Nikam B; Singh D; Pooja ; Kalidas N; Singh S; Mumtaz ; Bhardwaj AK; Mankotia DS; Ringe RP; Gupta N; Tripathi S; Mishra RPN
    Vaccine; 2024 Aug; 42(20):126099. PubMed ID: 38981743
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    Nambulli S; Escriou N; Rennick LJ; Demers MJ; Tilston-Lunel NL; McElroy AK; Barbeau DJ; Crossland NA; Hoehl RM; Schrauf S; White AG; Borish HJ; Tomko JA; Frye LJ; Scanga CA; Flynn JL; Martin A; Gerke C; Hartman AL; Duprex WP
    J Virol; 2024 May; 98(5):e0176223. PubMed ID: 38563762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays.
    Esposito D; Mehalko J; Drew M; Snead K; Wall V; Taylor T; Frank P; Denson JP; Hong M; Gulten G; Sadtler K; Messing S; Gillette W
    Protein Expr Purif; 2020 Oct; 174():105686. PubMed ID: 32504802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection.
    Lapp SA; Edara VV; Lu A; Lai L; Hussaini L; Chahroudi A; Anderson LJ; Suthar MS; Anderson EJ; Rostad CA
    PLoS One; 2021; 16(8):e0256482. PubMed ID: 34449792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
    Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
    Romeo A; Iacovelli F; Falconi M
    Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of SARS-CoV-2-Specific IgY Antibodies: Production, Reactivity, and Neutralizing Capability against Virus Variants.
    Schön J; Aebischer A; Halwe NJ; Ulrich L; Hoffmann D; Reiche S; Beer M; Grund C
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
    Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
    Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.
    Chen WH; Tao X; Agrawal AS; Algaissi A; Peng BH; Pollet J; Strych U; Bottazzi ME; Hotez PJ; Lustigman S; Du L; Jiang S; Tseng CK
    Vaccine; 2020 Nov; 38(47):7533-7541. PubMed ID: 33039209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-beta-coronavirus subunit vaccine prevents SARS-CoV-2 Omicron, SARS-CoV, and MERS-CoV challenge.
    Wang G; Verma AK; Guan X; Bu F; Odle AE; Li F; Liu B; Perlman S; Du L
    J Virol; 2024 Sep; 98(9):e0037624. PubMed ID: 39189731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
    Konrath KM; Liaw K; Wu Y; Zhu X; Walker SN; Xu Z; Schultheis K; Chokkalingam N; Chawla H; Du J; Tursi NJ; Moore A; Adolf-Bryfogle J; Purwar M; Reuschel EL; Frase D; Sullivan M; Fry B; Maricic I; Andrade VM; Iffland C; Crispin M; Broderick KE; Humeau LMPF; Patel A; Smith TRF; Pallesen J; Weiner DB; Kulp DW
    Cell Rep; 2022 Feb; 38(5):110318. PubMed ID: 35090597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
    Laczkó D; Hogan MJ; Toulmin SA; Hicks P; Lederer K; Gaudette BT; Castaño D; Amanat F; Muramatsu H; Oguin TH; Ojha A; Zhang L; Mu Z; Parks R; Manzoni TB; Roper B; Strohmeier S; Tombácz I; Arwood L; Nachbagauer R; Karikó K; Greenhouse J; Pessaint L; Porto M; Putman-Taylor T; Strasbaugh A; Campbell TA; Lin PJC; Tam YK; Sempowski GD; Farzan M; Choe H; Saunders KO; Haynes BF; Andersen H; Eisenlohr LC; Weissman D; Krammer F; Bates P; Allman D; Locci M; Pardi N
    Immunity; 2020 Oct; 53(4):724-732.e7. PubMed ID: 32783919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discordant Antigenic Properties of Soluble and Virion SARS-CoV-2 Spike Proteins.
    Kumar S; Dasgupta S; Sajadi MM; Snyder GA; DeVico AL; Ray K
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
    Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
    Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
    Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
    Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.
    Saunders KO; Lee E; Parks R; Martinez DR; Li D; Chen H; Edwards RJ; Gobeil S; Barr M; Mansouri K; Alam SM; Sutherland LL; Cai F; Sanzone AM; Berry M; Manne K; Bock KW; Minai M; Nagata BM; Kapingidza AB; Azoitei M; Tse LV; Scobey TD; Spreng RL; Rountree RW; DeMarco CT; Denny TN; Woods CW; Petzold EW; Tang J; Oguin TH; Sempowski GD; Gagne M; Douek DC; Tomai MA; Fox CB; Seder R; Wiehe K; Weissman D; Pardi N; Golding H; Khurana S; Acharya P; Andersen H; Lewis MG; Moore IN; Montefiori DC; Baric RS; Haynes BF
    Nature; 2021 Jun; 594(7864):553-559. PubMed ID: 33971664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potently neutralizing and protective human antibodies against SARS-CoV-2.
    Zost SJ; Gilchuk P; Case JB; Binshtein E; Chen RE; Nkolola JP; Schäfer A; Reidy JX; Trivette A; Nargi RS; Sutton RE; Suryadevara N; Martinez DR; Williamson LE; Chen EC; Jones T; Day S; Myers L; Hassan AO; Kafai NM; Winkler ES; Fox JM; Shrihari S; Mueller BK; Meiler J; Chandrashekar A; Mercado NB; Steinhardt JJ; Ren K; Loo YM; Kallewaard NL; McCune BT; Keeler SP; Holtzman MJ; Barouch DH; Gralinski LE; Baric RS; Thackray LB; Diamond MS; Carnahan RH; Crowe JE
    Nature; 2020 Aug; 584(7821):443-449. PubMed ID: 32668443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.